$71.35 $0.19 (0.3%)

04:30 PM EST on 02/19/20

Global Blood Therapeutics (NASDAQ:GBT)

CAPS Rating: 4 out of 5

Current Price $71.35 Mkt Cap $4.3B
Open $71.83 P/E Ratio 0.00
Prev. Close $71.16 Div. (Yield) $0.00 (0.0%)
Daily Range $70.72 - $72.79 Volume 379,117
52-Wk Range $61.80 - $87.54 Avg. Daily Vol. 850,025

Caps

How do you think NASDAQ:GBT will perform against the market?

Add Stock to CAPS Watchlist

All Players

40 Outperform
1 Underperform
 

All-Star Players

13 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:GBT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

pchop12316 (< 20)
Submitted August 13, 2015

excellent price entry point

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:GBT VS S&P 500 (SPY)

NASDAQ:GBT Summary

Fools bullish on NASDAQ:GBT are also bullish on:

Fools bearish on NASDAQ:GBT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about GBT.

Recs

0
Member Avatar odocoileus (41.47) Submitted: 1/26/2020 2:26:43 AM : Outperform Start Price: $47.00 NASDAQ:GBT Score: +23.40

In Longview CO in the 80's there was a bin of molasses that ruptured and flowed out over the streets in a 3-ft wall of goo that would have made for a good horror flick. That's what I picture after a biotech finally gets FDA approval. They are stuck in a morass, trying to move forward through the goo after the excitement of approval is over. I green-thumbed GBT before approval and patted myself on the back when it came through, but now they have to actually sell an $80,000/yr product over the debate on drug pricing. I'm hanging on to this ticker in real life because I think it is the best product right now for SCD, and my weakness is good science. Even if gene therapy eventually comes to fruition, this product can be used in conjunction for those individuals that are not completely cured. It may be a while before we see sales numbers that mean anything, and a more sensible person might take profits and wait to see sales numbers to buy back in. My rating is in the 20's, and I've not been accuse of being sensible lately. So why are you listening to me? Do your own DD.

Recs

0
Member Avatar mdriver78 (70.31) Submitted: 1/24/2020 9:03:31 AM : Outperform Start Price: $78.70 NASDAQ:GBT Score: -11.23

potential big winner in treating blood cancers like acute myeloid leukemia (AML). The company is on track to report Phase 2 data from its AML program later this year.

In the meantime, however, the GBT partnership news is sending SYRS shares up sharply over the past month.

Syros’ therapies, like its AML drug called SY-1425, work by controlling how genes are expressed. In cancer, this could be a very valuable approach, since shutting down cancer genes could help create new treatments.

But Syros’ gene expression platform could be broadly applicable to other types of disease including sickle cell disease and beta thalassemia.

Global Blood Therapeutics wants to tap into Syros’ drug discovery engine to find new targets and leads, with a primary interest in finding a way to induce the production of fetal hemoglobin through an oral drug.

Success means GBT will gain exclusive license to develop these leads into commercial therapies, potentially producing a functional cure. For Syros, success is a $20 million upfront payment, access to future milestone payments and three years of preclinical research payments.

Recs

0
Member Avatar TMFHaen (49.38) Submitted: 12/27/2019 4:58:28 PM : Outperform Start Price: $79.47 NASDAQ:GBT Score: -14.98

The FDA recently approved the launch of GBT's drug for sickle cell disease which aims to treat the root cause, not just symptoms.

Leaderboard

Find the members with the highest scoring picks in GBT.

Score Leader

jack0071

jack0071 (72.79) Score: +339.38

The Score Leader is the player with the highest score across all their picks in GBT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 98.63 2/10/2016 Outperform 5Y $13.38 +433.26% +80.20% +353.06 0 Comment
jack0071 72.79 12/28/2016 Outperform 5Y $14.60 +388.70% +49.32% +339.38 0 Comment
LifeScientist 25.15 3/11/2016 Outperform 3M $16.02 +345.38% +67.34% +278.04 1 Comment
portefeuille4 99.45 9/2/2016 Outperform 5Y $17.46 +308.65% +55.09% +253.56 0 Comment
walterknepper 88.79 2/3/2016 Outperform 5Y $18.61 +283.40% +79.50% +203.90 0 Comment
portefeuille2 98.97 8/17/2016 Outperform 5Y $21.65 +229.56% +55.19% +174.37 0 Comment
chad1510 88.28 7/10/2017 Outperform 3Y $28.55 +149.91% +39.83% +110.08 0 Comment
efarev 98.08 5/23/2017 Outperform 5Y $28.80 +147.74% +40.95% +106.79 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. BorderBandit 80.02 10/30/2017 Outperform 3M $34.70 +105.62% +31.61% +74.01 0 Comment
ACAL65 91.54 12/18/2017 Outperform 5Y $36.55 +95.21% +26.19% +69.02 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GBT.